Aug 19, 2024 · Pelage Pharmaceuticals recently announced its novel topical agent, PP405, has advanced to a phase 2a study for androgenetic alopecia, with enrollment currently underway …

Feb 18, 2024 · The Phase 1 trial evaluating PP405, a novel topical agent designed to treat androgenetic alopecia and other forms of hair loss, showed 0.05% PP405 topical treatment for …

Pelage is a regenerative medicine biotech developing innovative treatments for hair loss by activating hair follicle stem cells.

Feb 29, 2024 · Pelage Therapeutics (CA, USA) secures US$16.75 million to advance PP405, a small molecule that reactivates dormant hair follicle stem cells in alopecia.

In a few years, we may see PP405 or similar agents used alongside follicular unit extraction (FUE) and other transplant techniques to stimulate donor and recipient zones, boost yield, and …

Aug 14, 2024 · Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle …

Aug 21, 2024 · Pelage Pharmaceuticals, a clinical-stage regenerative medicine company, has initiated its Phase 2a trial for PP405, a topical small molecule designed to treat androgenetic …

Aug 14, 2024 · The first patients have been dosed in a phase 2a clinical trial of PP405 for the treatment of androgenetic alopecia, Pelage Pharmaceuticals announced in a press release.

Aug 14, 2024 · Regenerative medicine company Pelage Pharmaceuticals has secured a $14 million Series A-1 financing round and commenced its Phase 2a study evaluating its topical …

Jun 23, 2025 · PP405 demonstrated safety and efficacy in a phase 2a trial for androgenetic alopecia, meeting primary endpoints without systemic absorption. The therapy targets the …